Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years.


Journal

European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796

Informations de publication

Date de publication:
01 10 2020
Historique:
received: 14 11 2019
revised: 21 01 2020
accepted: 24 01 2020
pubmed: 6 2 2020
medline: 6 7 2021
entrez: 4 2 2020
Statut: ppublish

Résumé

There has been significant evolution in operative and post-transplant therapies following liver transplantation (LT). We sought to study their impact on cardiovascular (CV) mortality, particularly in the longer term. A retrospective cohort study was conducted of all adult LTs in Australia and New Zealand across three 11-year eras from 1985 to assess prevalence, modes, and predictors of early (≤30 days) and late (>30 days) CV mortality. A total of 4265 patients were followed-up for 37 409 person-years. Overall, 1328 patients died, and CV mortality accounted for 228 (17.2%) deaths. Both early and late CV mortality fell significantly across the eras (P < 0.001). However, CV aetiologies were consistently the leading cause of early mortality and accounted for ∼40% of early deaths in the contemporary era. Cardiovascular deaths occurred significantly later than non-cardiac aetiologies (8.8 vs. 5.2 years, P < 0.001). On multivariable Cox regression, coronary artery disease [hazard ratio (HR) 4.6, 95% confidence interval (CI) 1.2-21.6; P = 0.04] and era of transplantation (HR 0.44; 95% CI 0.28-0.70; P = 0.01) were predictors of early CV mortality, while advancing age (HR 1.05, 95% CI 1.02-1.10; P = 0.005) was an independent predictors of late CV mortality. Most common modes of CV death were cardiac arrest, cerebrovascular events, and myocardial infarction. Despite reductions in CV mortality post-LT over 30 years, they still account for a substantial proportion of early and late deaths. The late occurrence of CV deaths highlights the importance of longitudinal follow-up to study the efficacy of targeted risk-reduction strategies in this unique patient population.

Identifiants

pubmed: 32011663
pii: 5721356
doi: 10.1093/ehjqcco/qcaa009
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

243-253

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

Anoop N Koshy (AN)

Department of Cardiology, Austin Health, Melbourne, Victoria, Australia.
The University of Melbourne, Parkville, Victoria, Australia.

Paul J Gow (PJ)

The University of Melbourne, Parkville, Victoria, Australia.
Victorian Liver Transplant Unit, Austin Hospital, Melbourne, Victoria, Australia.

Hui-Chen Han (HC)

Department of Cardiology, Austin Health, Melbourne, Victoria, Australia.
The University of Melbourne, Parkville, Victoria, Australia.

Andrew W Teh (AW)

Department of Cardiology, Austin Health, Melbourne, Victoria, Australia.
The University of Melbourne, Parkville, Victoria, Australia.

Robert Jones (R)

The University of Melbourne, Parkville, Victoria, Australia.
Victorian Liver Transplant Unit, Austin Hospital, Melbourne, Victoria, Australia.

Adam Testro (A)

The University of Melbourne, Parkville, Victoria, Australia.
Victorian Liver Transplant Unit, Austin Hospital, Melbourne, Victoria, Australia.

Han S Lim (HS)

Department of Cardiology, Austin Health, Melbourne, Victoria, Australia.
The University of Melbourne, Parkville, Victoria, Australia.

Geoffrey McCaughan (G)

Department of Liver Transplantation, Royal Prince Alfred Hospital, Sydney, Australia.
University of Sydney, Sydney, Australia.

Gary P Jeffrey (GP)

Department of Liver Transplantation, Sir Charles Gardiner Hospital, Perth, Australia.
School of Medicine, University of Western Australia, Nedlands, Australia.

Michael Crawford (M)

Department of Liver Transplantation, Royal Prince Alfred Hospital, Sydney, Australia.
University of Sydney, Sydney, Australia.

Graeme Macdonald (G)

Department of Liver Transplantation, Princess Alexandra Hospital, Brisbane, Australia.
School of Medicine, The University of Queensland, Brisbane, Australia.

Jonathan Fawcett (J)

Department of Liver Transplantation, Princess Alexandra Hospital, Brisbane, Australia.
School of Medicine, The University of Queensland, Brisbane, Australia.

Alan Wigg (A)

Department of Liver Transplantation, Flinders Medical Centre, Adelaide, Australia.

John W C Chen (JWC)

Department of Liver Transplantation, Flinders Medical Centre, Adelaide, Australia.

Edward J Gane (EJ)

Auckland City Hospital, Auckland, New Zealand.

Stephen R Munn (SR)

Auckland City Hospital, Auckland, New Zealand.

David J Clark (DJ)

Department of Cardiology, Austin Health, Melbourne, Victoria, Australia.
The University of Melbourne, Parkville, Victoria, Australia.

Matias B Yudi (MB)

Department of Cardiology, Austin Health, Melbourne, Victoria, Australia.
The University of Melbourne, Parkville, Victoria, Australia.

Omar Farouque (O)

Department of Cardiology, Austin Health, Melbourne, Victoria, Australia.
The University of Melbourne, Parkville, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH